Sartorius AG · XETR:SRT
Sartorius — Investor Presentation (July 2024)
22 slides from Sartorius's investor presentation, July 2024
Slide 1: Simplifying Progress – Welcome to Sartorius
Simplifying Progress Welcome to Sartorius July 2024
Slide 2: Our ambition: Better health for more people
Our ambition: Better health for more people We empower scientists and engineers to simplify and accelerate progress in life science and bioprocessing, Mission enabling the development of new and better therapies and more affordable medicine. We are a magnet and dynamic platform for pioneers and lead
Slide 3: Sartorius in 2023 numbers
Sartorius in 2023 numbers ~€3.4bn Sales revenue 28.3% Profit margin1 14,500+ Employees 60+ Locations worldwide ~€560mn Investments in capacities 150+ Years of experience 2045 Target for climate neutrality 1 Underlying EBITDA margin 3
Slide 4: 14,500 employees united by strong values
14,500 employees united by strong values 113 Nationalities Sustainability Openness Enjoyment Growing profitably and Driving change Working in an energetic acting responsibly towards and progress and rewarding Younger than all stakeholders internally and externally environment 54% 40 years 39% Women
Slide 5: Two divisions with a clear focus on the life science industry
Two divisions with a clear focus on the life science industry Offers a wide array of innovative technologies for the manufacture of biopharmaceuticals and vaccines as well as cell 79% Sales 2023 21% and gene therapeutics Bioprocess Solutions Lab Products & Services ~€3.4bn Division Division Speciali
Slide 6: Enabling the discovery and production of biopharmaceuticals
Enabling the discovery and production of biopharmaceuticals Bioprocess Solutions Division Molecule Cell line and Upstream & development process development downstream production Quality | Testing | Validation Lab Products & Services Division 6
Slide 7: The promises of biologics: From established to new concepts
The promises of biologics: From established to new concepts What are biopharmaceuticals? Advantages ▪ Target only diseased cells ▪ Have fewer side effects ▪ Allow first-time or improved treatment of Consist of Obtained from living cells in Administered mainly illnesses, e.g. cancer, multiple scleros
Slide 8: Many biotech medications are highly effective, but very expensive
Many biotech medications are highly effective, but very expensive Rheumatism Blood cancer Hemophilia Monoclonal antibodies CAR-T cell therapy Gene therapy ~€12,000 ~€280,000 ~$3.5mn Annual cost of treatment in GER Cost per treatment in Europe Cost per treatment in the USA 8
Slide 9: Only one out of 10,000 new drug candidates reaches the market
Only one out of 10,000 new drug candidates reaches the market Drug discovery Process development Market approval Commercial production >€2bn ~10% >10 years Average costs of developing Probability of clinical success From drug discovery a successful drug (Phase I to approval) to approval Schematic ex
Slide 10: Helping researchers in the labs to accelerate drug discovery
Helping researchers in the labs to accelerate drug discovery Our ambition Our solutions Reduce costly trial & error Powerful bioanalytical tools and lab essentials Understand diseases Conduct experiments Live cell analysis Cell characterization Protein analysis Cell selection Make better use of data
Slide 11: Once discovered also the manufacture of biologics remains complex
Once discovered also the manufacture of biologics remains complex 11
Slide 12: Providing technologies to increase productivity in bioprocessing
Providing technologies to increase productivity in bioprocessing Our ambition Our solutions More efficient bioprocessing Technologies for all phases of drug manufacturing Set up safe and flexible processes Increase resource and material efficiency Media & reagents Bioreactors & fermenters Reduce inv
Slide 13: Offering integrated end-to-end manufacturing solutions
Offering integrated end-to-end manufacturing solutions Upstream Production of the desired drug Cell culture media & Seed Scale-up Production preparation cultivation Downstream Isolation and filling of the desired drug Final Cryo- Sterile Concen- Virus clearance Chroma- Clarification & filling preser
Slide 14: Helping customers to reduce their environmental footprint
Helping customers to reduce their environmental footprint ▪ No water-/energy- intensive cleaning Single-use Process Data ▪ Less cleanroom space, technologies intensification analytics less energy usage ▪ Higher yields Biostat® STR Bioreactors Linkit® AX Resolute® BioSMB Ambr® 250HT Perfusion Umetric
Slide 15: Cell and gene therapies: New modalities, new challenges
Cell and gene therapies: New modalities, new challenges Next generation biopharmaceuticals Enabling CGT: High need for innovation Viral Vectors mRNA Stem Cells Exosomes DNA New Vaccines Robustness of production process Yields, productivity, cost-per-dose Innovative treatments for patients Time-to-ma
Slide 16: Creating a technology platform for cell and gene therapy applications
Creating a technology platform for cell and gene therapy applications Up & downstream solutions Biological Albumedix Polyplus CellGenix Xell Industries Cell line development, Cell culture Growth factors Media and Recombinant Transfection plasmid design & media and cytokines supplements Albumin reage
Slide 17: How we innovate
How we innovate Own Product Development Acquisitions Cooperations in areas of core competencies of complementary technologies with partners leading in their fields Separation Cell cultivation Media & reagents Chromatography Nanoparticles Bioprinting technologies Artificial Lab analysis Automation Bi
Slide 18: Resilient global setup, well prepared for further growth
Resilient global setup, well prepared for further growth Customer proximity Ann Arbor, Michigan, USA Songdo, South Korea Freiburg, Germany Redundant capacity Bioanalytical products & services Media, bags, filtration, labs, training Cell culture components Operational excellence ~12 % Expected capex
Slide 19: Strong financial track record; profitable growth
Strong financial track record; profitable growth High volatility during and post pandemic Ø Annual growth 4100 3900 ~15% 2014-2023 59,5 57,5 3700 3500 ~€3.4bn 55,5 53,5 on prior-year 49,5 51,5 3300 3100 2900 level, with 47,5 45,5 2700 2500 bandwith of +/-43,5 lsd % growth 39,5 41,5 2300 2100 1900 34
Slide 20: Ambitious midterm targets backed by strong market fundamentals
Ambitious midterm targets backed by strong market fundamentals Ambition to 2028 Growing and aging Clear strategy world population Expanding market for biopharmaceuticals incl. Competitive, integrated Low double-digit product portfolio avg. annual sales growth1 biosimilars Dynamic market segment of S
Slide 21: Broad and ambitious sustainability agenda in implementation
Broad and ambitious sustainability agenda in implementation 2030 mid-term targets 2045 long-term target ~10% Zero 100% Net-zero av. reduction of CO2eq emission intensity p.a. (Scopes 1-3) avoidable1 emissions in Scopes 1 and 2 electricity from renewable sources emissions Decarbonization of the entir
Slide 22: Simplifying Progress
Simplifying Progress Sartorius AG Corporate Communications & IR Otto-Brenner-Straße 20 37079 Göttingen Germany